Leprosy is an ancient disease, yet every year it continues to affect 200,000 people across the world. Thanks to freely available multi-drug therapy, the number of people affected has dropped dramatically over the past decades. However, it has not been enough to eliminate leprosy and men, women and children continue to be diagnosed year-on-year.
To reach Zero Leprosy, we must end its transmission. ILEP and its members are working with the Novartis Foundation for Sustainable Development and national leprosy programs to interrupt the transmission of leprosy. In pilot sites across Asia, Africa and Latin America, the collaboration aims at introducing leprosy post-exposure prophylaxis (PEP) for persons who have been in contact with newly diagnosed patients to decrease their risk of developing leprosy.
Find out more about the LPEP project.